INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 214 filers reported holding INOVIO PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 1.82 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $255,082 | -48.2% | 311,076 | -1.5% | 0.00% | -100.0% |
| Q4 2022 | $492,793 | -3.0% | 315,893 | +7.2% | 0.00% | 0.0% |
| Q3 2022 | $508,000 | +8.3% | 294,653 | +8.8% | 0.00% | 0.0% |
| Q2 2022 | $469,000 | -51.4% | 270,910 | +0.7% | 0.00% | 0.0% |
| Q1 2022 | $966,000 | -33.2% | 269,032 | -7.2% | 0.00% | -50.0% |
| Q4 2021 | $1,446,000 | -28.4% | 289,812 | +2.7% | 0.00% | -33.3% |
| Q3 2021 | $2,020,000 | -23.5% | 282,122 | -1.0% | 0.00% | 0.0% |
| Q2 2021 | $2,642,000 | +1.9% | 284,955 | +2.0% | 0.00% | 0.0% |
| Q1 2021 | $2,592,000 | +22.1% | 279,359 | +16.5% | 0.00% | 0.0% |
| Q4 2020 | $2,122,000 | -22.9% | 239,810 | +1.1% | 0.00% | -25.0% |
| Q3 2020 | $2,753,000 | -52.9% | 237,288 | +9.4% | 0.00% | -60.0% |
| Q2 2020 | $5,846,000 | +448.4% | 216,923 | +51.4% | 0.01% | +400.0% |
| Q1 2020 | $1,066,000 | +128.3% | 143,240 | +1.2% | 0.00% | +100.0% |
| Q4 2019 | $467,000 | +61.0% | 141,590 | +0.2% | 0.00% | 0.0% |
| Q3 2019 | $290,000 | -30.1% | 141,291 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $415,000 | -17.5% | 141,291 | +4.9% | 0.00% | 0.0% |
| Q1 2019 | $503,000 | -1.6% | 134,739 | +5.5% | 0.00% | 0.0% |
| Q4 2018 | $511,000 | -28.0% | 127,738 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $710,000 | +42.9% | 127,738 | +0.7% | 0.00% | 0.0% |
| Q2 2018 | $497,000 | -14.9% | 126,899 | +2.3% | 0.00% | 0.0% |
| Q1 2018 | $584,000 | +10.2% | 124,063 | -3.4% | 0.00% | 0.0% |
| Q4 2017 | $530,000 | -35.5% | 128,412 | -1.0% | 0.00% | -50.0% |
| Q3 2017 | $822,000 | -12.2% | 129,697 | +8.7% | 0.00% | 0.0% |
| Q2 2017 | $936,000 | +8.2% | 119,354 | -8.6% | 0.00% | 0.0% |
| Q1 2017 | $865,000 | -8.9% | 130,654 | -4.5% | 0.00% | 0.0% |
| Q4 2016 | $950,000 | -27.5% | 136,854 | -2.6% | 0.00% | -33.3% |
| Q3 2016 | $1,310,000 | +1.9% | 140,554 | +1.0% | 0.00% | 0.0% |
| Q2 2016 | $1,286,000 | -2.9% | 139,154 | -8.5% | 0.00% | 0.0% |
| Q1 2016 | $1,325,000 | +48.0% | 152,070 | +14.2% | 0.00% | +50.0% |
| Q4 2015 | $895,000 | +18.4% | 133,123 | +1.8% | 0.00% | 0.0% |
| Q3 2015 | $756,000 | -29.3% | 130,752 | -0.3% | 0.00% | -33.3% |
| Q2 2015 | $1,070,000 | +19.4% | 131,152 | +19.4% | 0.00% | +50.0% |
| Q1 2015 | $896,000 | -12.5% | 109,805 | -1.5% | 0.00% | 0.0% |
| Q4 2014 | $1,024,000 | -6.4% | 111,505 | +0.4% | 0.00% | -33.3% |
| Q3 2014 | $1,094,000 | -7.8% | 111,030 | +1.1% | 0.00% | 0.0% |
| Q2 2014 | $1,187,000 | – | 109,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |